FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309834888> ?p ?o ?g. }

• W4309834888 endingPage "357" @default.
• W4309834888 startingPage "342" @default.
• W4309834888 abstract "Clinical evaluation and cost analysis of mitomycin-C–augmented PreserFlo MicroShunt versus trabeculectomy. Retrospective cohort study across 3 teaching hospitals. A total of 134 consecutive eyes of 129 patients (70 undergoing MicroShunt, 64 trabeculectomy). Primary and secondary glaucoma cases with uncontrolled intraocular pressure (IOP) were included. Neovascular glaucoma and surgery combined with cataract extraction were excluded. The cost analysis used results from the clinical study to estimate operative costs (equipment and staff costs) and postoperative costs (follow-up visits, nonglaucoma medications, and postoperative procedures) per eye for PreserFlo and trabeculectomy. The primary clinical outcome measure was surgical failure (defined as IOP > 21 mmHg or < 20% reduction from baseline, IOP ≤ 5 mmHg, reoperation, or loss of light perception) or qualified and complete success (with or without medication) at 18 months. Secondary measures were IOP, glaucoma medications, visual acuity, mean deviation, time to cessation of steroid drops, complications, surgical time, follow-up visits, postoperative interventions, and reoperations. The cost analysis evaluated costs of PreserFlo compared with trabeculectomy. Baseline characteristics were similar, except for more non-White patients in the trabeculectomy group (51% Black and Asian vs. 32% MicroShunt, P = 0.02) and more cases with prior ab externo glaucoma surgery in the MicroShunt group (19% vs. 3% in the trabeculectomy group, P = 0.004). Overall, 59% of eyes had primary open-angle glaucoma. Mean follow-up was 19.9 months for both groups. At 18 months, surgical failure was 25% for MicroShunt compared with 35% for trabeculectomy (P = 0.18). Failure in MicroShunt cases was due to inadequate IOP reduction (84%) or reoperation for glaucoma (16%). Failure in trabeculectomy cases was due to inadequate IOP reduction (58%), persistent hypotony (29%), or reoperation for glaucoma (13%). Combined blebitis and endophthalmitis rate was 1.4% for MicroShunt and 3.1% for trabeculectomy. Cost analysis showed a savings of £245 to £566 per eye in the MicroShunt group, driven mostly by reduced postoperative procedures and follow-up visits. This is in contrast to prior randomized controlled trial data reporting the incremental cost of $2058 of PreserFlo over trabeculectomy. Our experience of introducing PreserFlo MicroShunt surgery showed it was safer than trabeculectomy and is a cost-saving and effective option that offers potential to free up highly limited National Health Service resources. Proprietary or commercial disclosure may be found after the references." @default.
• W4309834888 created "2022-11-29" @default.
• W4309834888 creator A5000669696 @default.
• W4309834888 creator A5018960148 @default.
• W4309834888 creator A5027656432 @default.
• W4309834888 creator A5034585263 @default.
• W4309834888 creator A5037247436 @default.
• W4309834888 creator A5050750176 @default.
• W4309834888 creator A5051728798 @default.
• W4309834888 creator A5052237148 @default.
• W4309834888 creator A5060748577 @default.
• W4309834888 creator A5060790070 @default.
• W4309834888 creator A5066620210 @default.
• W4309834888 creator A5070504786 @default.
• W4309834888 creator A5076774130 @default.
• W4309834888 creator A5077593677 @default.
• W4309834888 date "2023-07-01" @default.
• W4309834888 modified "2023-10-02" @default.
• W4309834888 title "Clinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United Kingdom" @default.
• W4309834888 cites W1483018182 @default.
• W4309834888 cites W1893203835 @default.
• W4309834888 cites W2044000286 @default.
• W4309834888 cites W2085815830 @default.
• W4309834888 cites W2137878858 @default.
• W4309834888 cites W2286552028 @default.
• W4309834888 cites W2772195262 @default.
• W4309834888 cites W2794070012 @default.
• W4309834888 cites W2984021260 @default.
• W4309834888 cites W3012318936 @default.
• W4309834888 cites W3026425260 @default.
• W4309834888 cites W3036883342 @default.
• W4309834888 cites W3093526443 @default.
• W4309834888 cites W3097738774 @default.
• W4309834888 cites W3138170370 @default.
• W4309834888 cites W3165426643 @default.
• W4309834888 cites W3178660839 @default.
• W4309834888 cites W3183386760 @default.
• W4309834888 cites W3186642624 @default.
• W4309834888 cites W3214141958 @default.
• W4309834888 cites W3217677920 @default.
• W4309834888 cites W4231146585 @default.
• W4309834888 cites W4281677440 @default.
• W4309834888 cites W4284698590 @default.
• W4309834888 cites W4290691606 @default.
• W4309834888 doi "https://doi.org/10.1016/j.ogla.2022.11.006" @default.
• W4309834888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36427750" @default.
• W4309834888 hasPublicationYear "2023" @default.
• W4309834888 type Work @default.
• W4309834888 citedByCount "3" @default.
• W4309834888 countsByYear W43098348882023 @default.
• W4309834888 crossrefType "journal-article" @default.
• W4309834888 hasAuthorship W4309834888A5000669696 @default.
• W4309834888 hasAuthorship W4309834888A5018960148 @default.
• W4309834888 hasAuthorship W4309834888A5027656432 @default.
• W4309834888 hasAuthorship W4309834888A5034585263 @default.
• W4309834888 hasAuthorship W4309834888A5037247436 @default.
• W4309834888 hasAuthorship W4309834888A5050750176 @default.
• W4309834888 hasAuthorship W4309834888A5051728798 @default.
• W4309834888 hasAuthorship W4309834888A5052237148 @default.
• W4309834888 hasAuthorship W4309834888A5060748577 @default.
• W4309834888 hasAuthorship W4309834888A5060790070 @default.
• W4309834888 hasAuthorship W4309834888A5066620210 @default.
• W4309834888 hasAuthorship W4309834888A5070504786 @default.
• W4309834888 hasAuthorship W4309834888A5076774130 @default.
• W4309834888 hasAuthorship W4309834888A5077593677 @default.
• W4309834888 hasBestOaLocation W43098348881 @default.
• W4309834888 hasConcept C118487528 @default.
• W4309834888 hasConcept C141071460 @default.
• W4309834888 hasConcept C167135981 @default.
• W4309834888 hasConcept C2776508836 @default.
• W4309834888 hasConcept C2776766258 @default.
• W4309834888 hasConcept C2777824320 @default.
• W4309834888 hasConcept C2778257484 @default.
• W4309834888 hasConcept C2778527774 @default.
• W4309834888 hasConcept C2781092963 @default.
• W4309834888 hasConcept C71924100 @default.
• W4309834888 hasConceptScore W4309834888C118487528 @default.
• W4309834888 hasConceptScore W4309834888C141071460 @default.
• W4309834888 hasConceptScore W4309834888C167135981 @default.
• W4309834888 hasConceptScore W4309834888C2776508836 @default.
• W4309834888 hasConceptScore W4309834888C2776766258 @default.
• W4309834888 hasConceptScore W4309834888C2777824320 @default.
• W4309834888 hasConceptScore W4309834888C2778257484 @default.
• W4309834888 hasConceptScore W4309834888C2778527774 @default.
• W4309834888 hasConceptScore W4309834888C2781092963 @default.
• W4309834888 hasConceptScore W4309834888C71924100 @default.
• W4309834888 hasIssue "4" @default.
• W4309834888 hasLocation W43098348881 @default.
• W4309834888 hasLocation W43098348882 @default.
• W4309834888 hasOpenAccess W4309834888 @default.
• W4309834888 hasPrimaryLocation W43098348881 @default.
• W4309834888 hasRelatedWork W1991633257 @default.
• W4309834888 hasRelatedWork W2065895883 @default.
• W4309834888 hasRelatedWork W2081121150 @default.
• W4309834888 hasRelatedWork W2116765513 @default.
• W4309834888 hasRelatedWork W2332083955 @default.
• W4309834888 hasRelatedWork W2921728417 @default.
• W4309834888 hasRelatedWork W2943330015 @default.

• next